Research Article

Associations of Maternal Fructosamine before Delivery in Gestational Diabetes Mellitus Pregnancies with Neonatal Glucometabolic Disorders

Zhengxia Mao,1 Ruilin Wu,1 Huan Yu,1,2 Yujiao Zhang,2 Wenbin Dong,1,2 Lile Zou,3 and Xiaoping Lei1,2

1Division of Neonatology, Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
2Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
3Department of Histology and Embryology, Southwest Medical University, Luzhou, Sichuan, China

Correspondence should be addressed to Lile Zou; zoulilele@126.com and Xiaoping Lei; leixiaoping2020@swmu.edu.cn

Received 24 May 2022; Accepted 28 October 2022; Published 16 November 2022

Academic Editor: Eusebio Chiefari

Copyright © 2022 Zhengxia Mao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The offspring of pregnant women with gestational diabetes mellitus (GDM) are vulnerable to be glucometabolic disorders. However, to date, few current studies focused on the associations of maternal accumulated glucose exposure before delivery with neonatal glucometabolic disorders and large for gestational age (LGA) infants. This study is aimed at exploring the associations of maternal fructosamine (FMN) before delivery in GDM pregnant women with neonatal glucometabolic disorders in the first 3 days of life and LGA infants.

Methods. The study subjects were the GDM pregnant women, who gave birth in our hospital from September 1, 2018 to January 31, 2021, and their newborns. The maternal FMN adjusted by serum albumin (FMNALB) before delivery was selected as exposure factors. A multivariate logistical regression model was used to calculate the odds ratios (OR) for neonatal glucometabolic disorders, hypoglycemia needing intervention (<2.6 mmol/L), and glucose intolerance (>7.0 mmol/L) in the first 3 days and LGA infants.

Results. In GDM pregnant women, the newborns in the maternal FMNALB ≥ 75th percentile (≥ 5.89 mmol/g) group had higher risks in neonatal glucometabolic disorders (aOR 2.50, 95% CI 1.34-4.65, P = 0.004) and hypoglycemia (aOR 2.18, 95% CI 1.16-4.10, P = 0.016). However, FMNALB ≥ 75th percentile seemed to be not predictive of the glucose intolerance (aOR 1.76, 95% CI 0.82-3.79, P = 0.149) and LGA (aOR 1.56, 95% CI 0.81-3.02, P = 0.185). Further, in the sensitivity analysis, the newborns in the maternal FMNALB ≥ 90th percentile (≥6.40 mmol/g) group also had higher risks in neonatal glucometabolic disorders (aOR 5.70, 95% CI 2.18-14.89, P < 0.001) and hypoglycemia (aOR 3.72, 95% CI 1.48-9.31, P = 0.005). Conclusions. The maternal FMNALB before delivery in GDM pregnant women was a useful biomarker to identify the offspring with high risk of neonatal glucometabolic disorders. However, the association between maternal FMNALB and the risk of LGA infants was not so strong.

1. Introduction

As the most common metabolic complication in pregnant women, gestational diabetes mellitus (GDM) is related to many adverse perinatal outcomes [1]. The newborns of GDM pregnant women are vulnerable to developing hypoglycemia, hyperinsulinemia, and large for gestational age (LGA) infants [1, 2]. Furthermore, it is well known that the fetal insulin resistance is correlated with exposure to high blood glucose in utero, and the newborns of GDM pregnant women have higher fetal insulin resistance [3], so the glucose intolerance and drastic fluctuations of blood glucose can be observed in the newborns of GDM pregnant women in the early postnatal period. For severe or persistent hypoglycemia is related to neonatal brain injury and long-term neurological sequelae [4], most of the previous studies were focused on the prevention and treatment of GDM-related hypoglycemia. However, less attention was paid on the hyperglycemia induced by glucose...
intolerance in newborns of GDM pregnancies in the early postnatal periods. In fact, severe hyperglycemia was also associated with hypertonic dehydration, intracranial hemorrhage, retinopathy of prematurity (ROP), and other morbidities [5, 6]. In addition, LGA infants and newborn adiposity were associated with obesity, metabolic syndrome, and chronic disease in their later life [7, 8]. Therefore, great importance should be attached to the GDM-related neonatal glucometabolic disorders and LGA infants.

As is well known, the glycemic control in pregnancy is of great importance for GDM pregnant women and their fetuses. Few current studies focused on the associations of maternal accumulated glucose exposure before delivery with neonatal glucometabolic disorders and LGA infants. Hemoglobin A1c, a commonly used biomarker for monitoring glycemic control in type II diabetes mellitus, is inadequate due to anaemia or plasma volume expansion during pregnancy [9]. As the nonenzymatic reaction products of glucose with total serum proteins, fructosamine (FMN) can reflect the accumulated blood glucose levels in the past 2-3 weeks. Therefore, FMN has the potential to provide short-term glucose control monitoring where insulin and glucose change rapidly [10] and can be used to evaluate the glycemic control and maternal accumulated glucose exposure in GDM [11]. In the present study, the FMN within 3 days before delivery of GDM pregnant women was used as accumulated blood glucose exposure to explore its relation to neonatal glucometabolic disorders in the first 3 days and LGA infants.

2. Materials and Methods

2.1. Subjects. In this retrospective study, 264 pregnant women with GDM, who gave birth in our hospital from September 1, 2018 to January 31, 2021, and their newborns were enrolled as the final study subjects.

In the eligible study subjects (n = 379), the pregnancies with multiple births (n = 24) or combined with hypertensive disorders (n = 29), severe cardiac, hepatic, renal, endocrine, and immune system diseases in pregnancy (n = 21) were excluded. Besides, newborns with severe structural or chromosomal abnormality were excluded (n = 3). Finally, to reflect the accumulated blood glucose levels before delivery better, those pregnancies who missing FMN within 3 days (n = 38) before delivery were also excluded. This study protocol was reviewed and approved by the Medical Ethics Committee of our hospital (KY2020252).

2.2. Diagnostic Criteria, Exposure, and Outcomes. All data were collected through the hospital information system in this study. According to the criteria of International Association of Diabetes and Pregnancy Study Groups (IADPSG) [12], all pregnant women underwent a 75 g oral glucose tolerance test (OGTT) between the 24th and 28th gestation weeks. GDM was diagnosed based on at least one of the conditions as follows: fasting blood glucose (FBG) ≥ 5.1 mmol/L, 1h after glucose load ≥ 10.0 mmol/L, or 2h after glucose load ≥ 8.5 mmol/L [12].

For more than 70% of FMN coming from the productions of blood glucose combined with plasma albumin, the corrected FMN by plasma albumin (FMN_{ALB}) can better reflect the correlations between FMN and accumulated blood glucose exposures [13, 14]. Therefore, the maternal FMN_{ALB} within 3 days before delivery was used as the exposure factor reflecting the accumulated blood glucose levels in the past 2-3weeks. For there is no recommended normal value for FMN_{ALB} in GDM pregnant women at present, we used FMN_{ALB} ≥ 75th percentile (5.89 mmol/g) as the cut-off value of poor glycemic control before delivery. Meanwhile, FMN_{ALB} ≥ 90th percentile (6.40 mmol/g) was used as the cut-off value for further sensitivity analysis.

In the clinical practice, all the newborns of GDM pregnant women were fed as early as possible after birth and routinely monitored blood glucose according to the guideline [15]. In this study, the initial neonatal blood glucose was detected by microblood glucose instrument before feeding within 30 minutes after birth using heel blood. For newborns with normal initial neonatal blood glucose, blood glucose was still monitored at the same time in the morning for 3 days.

Neonatal hypoglycemia is defined as neonatal whole blood glucose value < 2.2 mmol/L [16]. However, recent studies showed that neonatal blood glucose < 2.6 mmol/L was associated with short- and long-term morbidities and was widely used as the clinical intervention standard in newborns [17]. In our clinical practice, if the initial blood glucose > 1.4 mmol/L, < 2.6 mmol/L, and no clinical symptoms of hypoglycemia, the newborn infants were only fed with milk or breast milk, while other sever cases were immediately intravenously injected glucose 1.2 mL/kg and followed by intravenous infusion of glucose by 6-8 mg/(kg·min) [18]. The blood glucose values were monitored 30 minutes later and once per hour for all infants with abnormal initial blood glucose, until the blood glucose was normal and stable. In the present study, the blood glucose level at any time in first 3 days of life below 2.6 mmol/L was defined as the hypoglycemia needing intervention.

For newborns with normal glucose tolerance, the blood glucose will not exceed 7.0 mmol/L under routine feeding and/or low concentrations of glucose infusion [19]. In this study, under routine feeding and/or glucose infusion below 6-8 mg/(kg·min) in the first three days of life, the blood glucose values exceed 7.0 mmol/L were defined as neonatal glucose intolerance. The neonatal glucometabolic disorders were included both hypoglycemia needing intervention and glucose intolerance.

Based on the fetal-weight reference adapted to Chinese [20], LGA was defined as birth weight by gestational age beyond the 90th percentile.

2.3. The Potential Confounding Factors. Referring to previous studies [18, 21–23], the demographic characteristics and potential confounding factors were collected, including maternal age (≥35 and <35 years), III degrees or meconium-stained amniotic fluid, placenta previa or placental abruption, antenatal corticosteroid use, and neonatal gestational age (<32, 32-33, 34-36, and ≥37 weeks), birth weight (<1500 g, 1500-2500 g, and >2500 g), weight for gestational age (small-for-gestational-age, appropriate-for-gestational-age, or LGA), and 1-minute Apgar score (≤7 and >7).
Table 1: The baseline demographic characteristics of GDM pregnant women with different levels of FMNALB before delivery.

|                          | FMNALB ≥ 75th percentile (N = 66) | FMNALB < 75th percentile (N = 198) | t/x²  | P    |
|--------------------------|-----------------------------------|------------------------------------|-------|------|
| Gestational age (d)      | 256 ± 23                          | 255 ± 24                           | 0.51  | 0.61 |
| Birth weight (g)         | 2921 ± 910                        | 2772 ± 794                         | 1.27  | 0.21 |
| Maternal age (years)     | 31 ± 5                            | 32 ± 5                             | -0.60 | 0.55 |
| 75 g glucose OGTT        |                                   |                                    |       |      |
| Fasting blood glucose (mmol/L) | 5.3 ± 1.0                        | 5.3 ± 1.1                          | 0.03  | 0.98 |
| 1 h after glucose load (mmol/L) | 10.3 ± 1.8                      | 10.3 ± 1.9                         | -0.03 | 0.98 |
| 2 h after glucose load (mmol/L) | 8.9 ± 2.0                        | 9.1 ± 2.1                          | -0.30 | 0.76 |
| Apgar 1 min ≤ 7, (n/N, %) | 11/66, 16.67%                     | 35/198, 17.68%                     | 0.04  | 0.85 |
| Apgar 5 min ≤ 7, (n/N, %) | 2/66, 3.03%                       | 7/198, 3.54%                       | 0.04  | 0.84 |
| Placenta previa or abruption, (n/N, %) | 8/66, 12.12%                    | 30/198, 15.15%                     | 0.37  | 0.54 |
| III degrees or meconium-stained amniotic fluid, (n/N, %) | 11/66, 16.67%                     | 30/198, 15.15%                     | 0.09  | 0.77 |
| Antenatal corticosteroid use, (n/N, %) | 14/66, 21.21%                    | 36/198, 18.18%                     | 0.30  | 0.59 |
| Insulin use during pregnancy, (n/N, %) | 11/66, 16.67%                    | 35/198, 17.68%                     | 0.04  | 0.85 |

GDM: gestational diabetes mellitus; FMNALB: the ratio of fructosamine to plasma albumin.

2.4. Laboratory Examinations. The FMN and plasma albumin were determined by CL-2000i automatic chemiluminescence immunoassay analyzer (Mindray Bio-Medical Electronics Co., Shenzhen, China). The neonatal peripheral blood glucose values were performed using an i-Sens blood glucose meter and test strips.

2.5. Statistical Analysis. SAS 9.4 (SAS Institute, Cary, NC, USA) software was used for data processing and analysis. Multivariate logistical regression model was used to calculate the adjusted odds ratios (ORs) and 95% confidence interval (CI) of maternal FMNALB before delivery for neonatal glucometabolic disorders, hypoglycemia needing intervention, glucose intolerance, and LGA infants.

3. Results

3.1. The Baseline Characteristics of GDM Pregnant Women with Different Levels of FMNALB before Delivery. As shown in Table 1, there were no significant differences in the baseline characteristics between the groups with maternal FMNALB ≥ 75th percentile and maternal FMNALB < 75th percentile.

3.2. The Associations between the Maternal FMNALB before Delivery and Neonatal Glucometabolic Disorders. As shown in Table 2, compared to the newborns of the GDM pregnant women with FMNALB < 75th percentile, the newborns in maternal FMNALB ≥ 75th percentile group had higher risks in neonatal glucometabolic disorders (aOR 2.50, 95% CI 1.34-4.65, P = 0.004) and hypoglycemia needing intervention (aOR 2.18, 95% CI 1.16-4.10, P = 0.016). However, no significant increased risk of glucose intolerance (aOR 1.76, 95% CI 0.82-3.79, P = 0.149) was observed in infants born to GDM mothers with FMNALB ≥ 75th percentile.

Further, in the sensitivity analysis, compared to the newborns of GDM pregnant women with FMNALB < 90th percentile, the newborns in maternal FMNALB ≥ 90th percentile group also had higher risks in neonatal glucometabolic disorders (aOR 5.70, 95% CI 2.18-14.89, P < 0.001) and hypoglycemia (aOR 3.72, 95% CI 1.48-9.31 P = 0.005). Similarly, for the risk in glucose intolerance, no significant difference existed between two groups (aOR 2.21; 95% CI 0.80-6.12; P = 0.125) (Table 2).

3.3. The Association between the Maternal FMNALB before Delivery and the Risk of LGA. As shown in Table 3, the risk of LGA did not significantly increase (OR = 1.56, 95% CI 0.81-3.02, P = 0.185) in infants born to mothers with FMNALB ≥ 75th percentile.

4. Discussion

In the present study, using maternal FMNALB as an indicator to reflect the short-term accumulated blood glucose levels, the results showed that maternal FMNALB before delivery was associated with the neonatal glucometabolic disorders in the first 3 days. It suggested that FMNALB before delivery was an alternative maternal biomarker to identify the high-risk newborns for glucometabolic disorders in GDM pregnant women.

Previous studies have confirmed that the newborns of GDM pregnant women had higher risk of neonatal hypoglycemia, and severe or persistent neonatal hypoglycemia can lead to neonatal brain injury and long-term neurological sequelae [4]. The fetus receives glucose from the mother achieving fetal plasma glucose concentrations 70-80% of the maternal level. As insulin does not cross the placenta, the fetuses of GDM pregnant women have to secrete more insulin to maintain blood glucose in the normal range [24], and the transient high insulin level can cause neonatal
hypoglycemia after birth [25]. Our results confirmed that higher maternal FMNALB before delivery can be a prenatal predictor of hypoglycemia needing intervention in the offspring. In addition, the results from the sensitivity analysis implicated that extremely high maternal FMNALB should be more vigilant for neonatal hypoglycemia.

Based on the developmental Origins of Health and Disease (DOHaD) theory, exposure to adverse environments, including hyperglycemia, during the early life can lead to fetal metabolic programming [26]. The fetus of GDM pregnant women exposed to intrauterine hyperglycemia and their own hyperinsulinemia can induce abnormal metabolic programming through epigenetic modification such as DNA methylation [27, 28]. And the secretion of insulin from pancreatic β-cells and the insulin sensitivity of the peripheral target organs will decrease [29], which can induce the offspring to be insulin resistance, abnormal glucose and lipid metabolism, and overweight/obesity in the short- and long-term after birth [30, 31]. Previous studies have reported that the glucose metabolic disorder of GDM pregnant women was a key factor in the development of insulin resistance in their offspring [32]. Higher maternal blood glucose levels and severe insulin resistance in the third trimester of pregnancy can cause fetal insulin resistance [3, 33]. In this study, neonatal glucose metabolic disorder may be the early manifestation of the abnormal glucometabolic programming in the offspring of GDM pregnant women. Intrauterine hyperglycemia exposure may damage the fetal glucometabolic function, leading to glucose metabolic disorder. Our results showed that, even with no statistical significance for the small sample size, the risk of glucose intolerance was also increased to some extent in the newborns of GDM mothers with higher FMNALB before delivery. As we all know, in GDM pregnant women, the degree of insulin resistance increases in late pregnancy, and the glucose metabolism also changes rapidly at the same time, so the blood glucose may also changes fast before delivery [34]. As an indicator to reflect the glucose exposure in the past 2-3 weeks, FMN before delivery was weak in our study.

**Table 2:** The associations between the maternal FMNALB before delivery and neonatal glucometabolic disorders.

| FMNALB ≥ 75th percentile (n/N, %) | FMNALB < 75th percentile (n/N, %) | OR (95% CI) | P     | aOR (95% CI) | P     |
|-----------------------------------|-----------------------------------|-------------|-------|--------------|-------|
| Neonatal glucometabolic disorders | 37/66, 56.06%                     | 76/198, 38.38% | 2.05 (1.17-3.60) | 0.013 | 2.50 (1.34-4.65) | 0.004 |
| Neonatal hypoglycemia            | 29/66, 43.94%                     | 59/198, 29.80% | 1.85 (1.04-3.28) | 0.036 | 2.18 (1.16-4.10) | 0.016 |
| Neonatal glucose intolerance     | 13/66, 19.70%                     | 26/198, 13.13% | 1.62 (0.78-3.38) | 0.196 | 1.76 (0.82-3.79) | 0.149 |

**Table 3:** The association between the maternal FMNALB before delivery with the risk of LGA infants.

| FMNALB ≥ 75th percentile (n/N, %) | FMNALB < 75th percentile (n/N, %) | OR (95% CI) | P     |
|-----------------------------------|-----------------------------------|-------------|-------|
| LGA                               | 17/66, 25.76%                     | 36/198, 18.18% | 1.56 (0.81-3.02) | P = 0.185 |
Our study also has several potential limitations. The selection bias was not avoided from missing $\text{FMN}_{\text{ALB}}$ before delivery in GDM pregnant women. However, the study subjects were stratified according to the levels of maternal $\text{FMN}_{\text{ALB}}$ and had no missing data of the neonatal outcomes, which could significantly reduce the selection bias. Secondly, as a tertiary health center in rural area of Southwest of China, for the poor awareness on the self-management of blood glucose, our hospital accepted many GDM pregnancies with poor glycemic control before delivery. Therefore, the incidence of adverse perinatal outcome in our subjects was a bit high; the findings from our study subjects may not be widely suitable for all GDM pregnant women. But in the another hand, it came from the real world of rural area and may give some lights on the management of GDM in the developing country with less medical facility. Moreover, in this study, we only discussed the newborns’ glucose metabolism in the early postnatal stage, but we cannot know whether the glucose metabolism is impaired in the future. We guess that neonatal glucose metabolic disorder may be the early manifestation of long-term glucometabolic impairment, which needs more cohort studies to confirm. However, to our knowledge, the present study is the first study on exploring the association between the maternal $\text{FMN}_{\text{ALB}}$ before delivery and the neonatal glucometabolic disorders in early life.

5. Conclusion

In conclusion, our results showed a positive value of maternal $\text{FMN}_{\text{ALB}}$ before delivery in GDM pregnant women in identifying newborns with high risk of neonatal glucometabolic disorders.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval

This study protocol was reviewed and approved by the Medical Ethics Committee of our hospital (KY2020252).

Disclosure

The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Conflicts of Interest

Zhengxia Mao declared no potential conflicts of interests with respect to the authorship and/or publication of this article. Wenbin Dong declared no potential conflicts of interests with respect to the authorship and/or publication of this article. Lié Zou declared no potential conflicts of interests with respect to the authorship and/or publication of this article. Xiaoping Lei declared no potential conflicts of interests with respect to the authorship and/or publication of this article.

Authors’ Contributions

Zhengxia Mao and Ruilin Wu contributed equally and should be considered joint first authors.

Acknowledgments

Funding for this project was provided by the Sichuan Science and Technology Program, grant no. 2019YJ0696 and the Science and Technology Strategic Cooperation Programs of Luzhou Municipal People’s Government and Southwest Medical University, grant no. 2021LZXNYD-J21 to Xiaoping Lei.

References

[1] P. Saravanam, L. A. Magee, A. Banerjee et al., “Gestational diabetes: opportunities for improving maternal and child health,” The Lancet Diabetes & Endocrinology, vol. 8, no. 9, pp. 793–800, 2020.
[2] P. Catalano, H. McIntyre, J. Cruickshank et al., “The hyperglycaemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes,” Diabetes Care, vol. 35, no. 4, pp. 780–786, 2012.
[3] Q. Wang, R. Huang, B. Yu et al., “Higher fetal insulin resistance in Chinese pregnant women with gestational diabetes mellitus and correlation with maternal insulin resistance,” PLoS One, vol. 8, no. 4, article e59845, 2013.
[4] M. Roep, R. S. Dafsari, S. Kummer et al., “Risk factors for brain injury after transient or persistent persistent hyperinsulinemic hypoglycemia in neonates,” Hormone Research in Pediatrics, vol. 91, pp. 228–229, 2019.
[5] E. Kerminvaut-Duchemin, G. le Meur, F. Plaisant et al., “Thresholds of glycaemia, insulin therapy, and risk for severe retinopathy in premature infants: a cohort study,” PLoS Medicine, vol. 17, no. 12, article e1003477, 2020.
[6] C. Blanco, J. Baillargeon, R. Morrison, and A. Gong, “Hyperglycaemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities,” Journal of Perinatology, vol. 26, no. 12, pp. 737–741, 2006.
[7] J. L. Josefson, D. M. Scholtens, A. Kuang et al., “Newborn adiposity and cord blood C-peptide as mediators of the maternal metabolic environment and childhood adiposity,” Diabetes Care, vol. 44, no. 5, pp. 1194–1202, 2021.
[8] Y. H. Hong and J. E. Lee, “Large for gestational age and obesity-related comorbidities,” Journal of Obesity & Metabolic Syndrome, vol. 30, no. 2, pp. 124–131, 2021.
[9] S. Iuliano, A. E. Greco, M. Mirabella et al., “Predicting the response to SGLT-2 inhibitors as add-on therapy to multiple day injection insulin with glycated albumin: a pilot study,” Minerva Endocrinol (Torino), 2022.
[10] E. Selvin, A. Rawlings, M. Grans et al., “Fructosamine and glycated albumin for risk stratification and prediction of incident
diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study,” The Lancet Diabetes & Endocrinology, vol. 2, no. 4, pp. 279–288, 2014.

[11] P. Poupon, N. Foussard, C. Helmer et al., “Serum fructosamine predicts macrosomia in well-controlled hyperglycaemic pregnant women: an observational cross-sectional study,” Diabetes & Metabolism, vol. 46, no. 3, pp. 219–222, 2020.

[12] International Association of Diabetes and Pregnancy Study Groups Consensus Panel, “International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy,” Diabetes Care, vol. 33, no. 3, pp. 676–682, 2010.

[13] M. Johnson, R. Keyho, N. Blackburn et al., “Glycated serum protein genetics and pleiotropy with cardiometabolic risk factors,” Journal of Diabetes Research, vol. 2019, Article ID 2310235, 9 pages, 2019.

[14] S. Rodríguez-Segade, J. Rodriguez, and F. Camiña, “Corrected fructosamine improves both correlation with HbA1C and diagnostic performance,” Clinical Biochemistry, vol. 50, no. 3, pp. 110–115, 2017.

[15] “14. Management of diabetes in pregnancy: <i>standards of medical care in diabetes-2021</i>,” Diabetes Care, vol. 44, Suppl 1, pp. S200–S210, 2021.

[16] D. Adamkin, “Neonatal hypoglycemia,” Seminars in Fetal & Neonatal Medicine, vol. 22, no. 1, pp. 36–41, 2017.

[17] D. Wackernagel, A. Gustafsson, A. Edstedt Bonamy et al., “Swedish national guideline for prevention and treatment of neonatal hypoglycaemia in newborn infants with gestational age ≥35 weeks,” Acta Paediatrica (Oslo, Norway: 1992), vol. 109, no. 1, pp. 31–44, 2020.

[18] V. Kallem, A. Pandita, and G. Gupta, “Hypoglycemia: when to treat?,” Clinical Medicine Insights: Pediatrics, vol. 11, p. 117955651774891, 2017.

[19] A. Ogilvy-Stuart and K. Beardsall, “Management of hyperglycaemia in the preterm infant,” Archives of Disease in Childhood, Fetal and Neonatal Edition, vol. 95, no. 2, pp. F126–F131, 2010.

[20] R. T. Mikolajczyk, J. Zhang, A. P. Betran et al., “A global reference for fetal-weight and birthweight percentiles,” Lancet, vol. 377, no. 9780, pp. 1855–1861, 2011.

[21] T. Esakoff, A. Guillet, and A. Caughhey, “Does small for gestational age worsen outcomes in gestational diabetics?,” Journal of Maternal-Fetal & Neonatal Medicine, vol. 30, no. 8, pp. 890–893, 2017.

[22] K. Pettit, S. Tran, E. Lee, and A. Caughhey, “The association of antenatal corticosteroids with neonatal hyperglycemia and hyperbilirubinemia,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 27, no. 7, pp. 683–686, 2014.

[23] D. Adamkin, “Postnatal glucose homeostasis in late-preterm and term infants,” Pediatrics, vol. 127, no. 3, pp. 575–579, 2011.

[24] P. Olmos, G. Borzone, and A. Poblete, “Gestational diabetes: glycemic control in the last two weeks before delivery contributes to newborn insulinemia,” Journal of Obstetrics and Gynaecology Canada, vol. 40, no. 11, pp. 1445–1452, 2018.

[25] S. Koivunen, A. Torkki, A. Bloigu et al., “Towards national comprehensive gestational diabetes screening – consequences for neonatal outcome and care,” Acta Obstetricia et Gynecologica Scandinavica, vol. 96, no. 1, pp. 106–113, 2017.

[26] E. Yeung, C. Robledo, N. Boghossian, C. Zhang, and P. Mendola, “Developmental origins of cardiovascular disease,” Current Epidemiology Reports, vol. 1, no. 1, pp. 9–16, 2014.

[27] J. St-Pierre, M. Hivert, P. Perron et al., “IGF2 DNA methylation is a modulator of newborn’s fetal growth and development,” Epigenetics, vol. 7, no. 10, pp. 1125–1132, 2012.

[28] L. Bouchard, S. Thibault, S. Guay et al., “Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy,” Diabetes Care, vol. 33, no. 11, pp. 2436–2441, 2010.

[29] N. Bush, P. Chandler-Laney, D. Rouse, W. Granger, R. Oster, and B. Gower, “Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 5, pp. E803–E809, 2011.

[30] M. E. Bianco, A. Kuang, J. L. Josefson et al., “Hyperglycemia and adverse pregnancy outcome follow-up study: newborn anthropometrics and childhood glucose metabolism,” Diabetologia, vol. 64, no. 3, pp. 561–570, 2021.

[31] D. Dabbeia, “The predisposition to obesity and diabetes in offspring of diabetic mothers,” Diabetes Care, vol. 30, Supplement_2, pp. S169–S174, 2007.

[32] M. Lacroix, E. Kina, and M. Hivert, “Maternal/fetal determinants of insulin resistance in women during pregnancy and in offspring over life,” Current Diabetes Reports, vol. 13, no. 2, pp. 238–244, 2013.

[33] X. Wang, T. Yang, J. Miao et al., “Correlation between maternal and fetal insulin resistance in pregnant women with gestational diabetes mellitus,” Clinical Laboratory, vol. 64, no. 6, pp. 945–953, 2018.

[34] U. Kampmann, S. Knorr, J. Fuglsang, and P. Ovesen, “Determinants of maternal insulin resistance during pregnancy: an updated overview,” Journal of Diabetes Research, vol. 2019, Article ID 5320156, 9 pages, 2019.

[35] N. Mendes, M. Alves, R. Andrade, R. Ribeiro, A. Papoila, and F. Serrano, “Association between glycated albumin, fructosamine, and HbA1c with neonatal outcomes in a prospective cohort of women with gestational diabetes mellitus,” International Journal of Gynaecology and Obstetrics, vol. 146, no. 3, pp. 326–332, 2019.

[36] J. Hawdon, “Postnatal metabolic adaptation and neonatal hypoglycaemia,” Paediatrics and Child Health, vol. 26, no. 4, pp. 135–139, 2016.